prikaz prve stranice dokumenta Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
  Preuzmi
PDF 1.16 MB
Znanstveni rad - Pregledni rad
Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
World J Gastroenterol, 22 (2016), 32; 7236-7251. urn:nbn:hr:184:683246
Mikolašević, Ivana; Orlić, Lidija; Franjić, Neven; Hauser, Goran; Štimac, Davor; Milić, Sandra

Citirajte ovaj rad

Mikolašević, I., Orlić, L., Franjić, N., Hauser, G., Štimac, D. i Milić, S. (2016). Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. World J Gastroenterol, 22. (32), 7236-7251. Preuzeto s https://urn.nsk.hr/urn:nbn:hr:184:683246

Mikolašević, Ivana, et al. "Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?." World J Gastroenterol, vol. 22, br. 32, 2016, str. 7236-7251. https://urn.nsk.hr/urn:nbn:hr:184:683246

Mikolašević, Ivana, Lidija Orlić, Neven Franjić, Goran Hauser, Davor Štimac i Sandra Milić. "Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?." World J Gastroenterol 22, br. 32 (2016): 7236-7251. https://urn.nsk.hr/urn:nbn:hr:184:683246

Mikolašević, I., et al. (2016) 'Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?', World J Gastroenterol, 22(32), str. 7236-7251. Preuzeto s: https://urn.nsk.hr/urn:nbn:hr:184:683246 (Datum pristupa: 26.12.2024.)

Mikolašević I, Orlić L, Franjić N, Hauser G, Štimac D, Milić S. Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. World J Gastroenterol [Internet]. 28.08.2016. [pristupljeno 26.12.2024.];22(32):7236-7251. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:683246

I. Mikolašević, L. Orlić, N. Franjić, G. Hauser, D. Štimac i S. Milić, "Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?", World J Gastroenterol, vol. 22, br. 32, str. 7236-7251, Kolovoz 2016. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:683246. [Citirano: 26.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:683246
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
AutorIvana Mikolašević
AutorLidija Orlić
AutorNeven Franjić
AutorGoran Hauser
AutorDavor Štimac
AutorSandra Milić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Currently, the routinely used modalities are unable to adequately determine the levels of steatosis and fibrosis (laboratory tests and ultrasonography) or cannot be applied as a screening procedure (liver biopsy). Among the non-invasive tests, transient elastography (FibroScan®, TE) with controlled attenuation parameter (CAP) has demonstrated good accuracy in quantifying the levels of liver steatosis and fibrosis in patients with NAFLD, the factors associated with the diagnosis and NAFLD progression. The method is fast, reliable and reproducible, with good intra- and interobserver levels of agreement, thus allowing for population-wide screening and disease follow-up. The initial inability of the procedure to accurately determine fibrosis and steatosis in obese patients has been addressed with the development of the obese-specific XL probe. TE with CAP is a viable alternative to ultrasonography, both as an initial assessment and during follow-up of patients with NAFLD. Its ability to exclude patients with advanced fibrosis may be used to identify low-risk NAFLD patients in whom liver biopsy is not needed, therefore reducing the risk of complications and the financial costs.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaWorld J Gastroenterol
Brojčani podacivol. 22, br. 32, str. 7236-7251
e-ISSN1007-9327
URN:NBNurn:nbn:hr:184:683246
Datum objave publikacije2016-08-28
URL dokumentahttps://www.wjgnet.com/1007-9327/full/v22/i32/7236.htm
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2017-09-17 12:56:39